Related Experiment Video

Updated: Jun 21, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

[Therapeutic monoclonal antibodies in hemato-oncology]

C Gennigens1, J Collignon, G Jerusalem

  • 1Service d'Oncologie Médicale, CHU de Liège, Belgique.

Revue Medicale De Liege
|August 1, 2009
PubMed

Insights

Monoclonal antibodies (mAbs) are advanced targeted therapies revolutionizing cancer treatment. These engineered proteins offer precise cancer cell targeting, improving outcomes for hematologic and solid malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Context:

  • Traditional cancer treatments like chemotherapy, hormonotherapy, and immunotherapy have limitations.
  • Advances in understanding cancer cell biology and signaling pathways have identified new therapeutic targets.
  • Targeted therapies represent a new class of drugs designed to interfere with specific cancer mechanisms.

Purpose:

  • To review the role and advancements of monoclonal antibodies (mAbs) in cancer therapy.
  • To highlight the development and application of mAbs as targeted treatments.
  • To discuss the current and future landscape of mAb-based cancer therapeutics.

Summary:

  • Monoclonal antibodies (mAbs) are a key type of targeted therapy, distinct from small molecule inhibitors.
  • mAbs function by targeting specific cell surface receptors or their ligands, blocking cancer cell activation and growth.
  • Significant progress in molecular engineering and target selection has enhanced the efficacy of therapeutic mAbs.

Impact:

  • Monoclonal antibodies have become established and efficient therapeutic tools in oncology.
  • Several mAbs are approved for treating various hematologic and solid tumors.
  • The continued development and expected future approvals promise expanded therapeutic options for cancer patients.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...